DEF: Actinium Pharmaceuticals Sets 2025 Annual Meeting Agenda

Actinium Pharmaceuticals, Inc. announces its 2025 Annual Meeting of Stockholders to address director elections, auditor ratification, and executive compensation advisory votes.

Summary

• The Annual Meeting of Stockholders will be held on November 26, 2025, at 9:30 a.m. Eastern Time, at The Garden City Hotel, 45 Seventh St, Garden City, NY 11530.
• Stockholders planning to attend in person must register in advance by November 20, 2025.
• Key proposals include the re-election of Ajit Shetty and June S. Almenoff as Class III directors for a three-year term, ratification of CBIZ CPAs P.C. as the independent auditor for fiscal year 2025, and non-binding advisory votes on named executive officer compensation and the frequency of future compensation votes.
• The Board of Directors unanimously recommends a vote FOR Proposals 1, 2, and 3, and EVERY THREE YEARS for Proposal 4.
• The Record Date for voting eligibility is October 15, 2025, with 31,195,891 shares of common stock outstanding.
• Marcum LLP was dismissed as the independent registered public accounting firm on May 8, 2025, following CBIZ CPAs P.C.'s acquisition of Marcum's attest business, and CBIZ was subsequently engaged.

Sentiment

Score: 3

Explanation: The filing outlines routine corporate governance matters for an annual meeting but reveals continued substantial net losses, a significant decline in Total Shareholder Return over recent years, and active class action and derivative lawsuits alleging misrepresentations. These factors collectively point to a negative sentiment regarding the company's recent performance and current challenges.

Positives

• The Board of Directors unanimously recommends the re-election of two Class III directors, Ajit Shetty and June S. Almenoff, suggesting continuity in governance.
• The appointment of CBIZ CPAs P.C. as the new independent registered public accounting firm ensures continued audit services following an acquisition.
• The Board has determined that the company's compensation programs do not encourage excessive risk and instead promote behaviors supporting sustainable value creation.
• The company has a Code of Business Conduct and Ethics, and anti-hedging/anti-pledging policies in place for directors, officers, and employees.

Negatives

• The company reported a net loss of $38,243,000 for 2024, following a net loss of $48,818,000 in 2023 and $33,017,000 in 2022, indicating persistent unprofitability.
• The Total Shareholder Return (TSR) based on an initial $100 investment significantly declined from $136.54 in 2022 to $65.13 in 2023 and further to $16.15 in 2024.
• The company is a defendant in a putative class action complaint filed March 27, 2025, alleging material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial.
• Two derivative shareholder complaints, consolidated into a Derivative Action, were filed in May 2025, alleging derivative liability for the same issues as the Securities Complaint.

Risks

• Litigation is subject to inherent uncertainties, and an adverse result in the ongoing Securities Complaint and Derivative Action may arise and harm the business.
• The Securities Complaint alleges material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial, which could impact future product development or market perception.
• The Derivative Complaints allege derivative liability against the company's directors and officers for the allegations made in the Securities Complaint, potentially leading to further legal and financial repercussions.
• The company's executive compensation program does not directly utilize Total Shareholder Return (TSR) or net loss as performance measures, which could be perceived as a misalignment of executive incentives with shareholder value.

Future Outlook

The Board recommends holding future advisory votes on executive compensation every three years, believing this provides sufficient time to evaluate compensation philosophy and practices in the context of long-term business results and allows observation of the impact of any changes. Lead plaintiffs in the Securities Complaint intend to file an amended complaint on or before August 25, 2025. The next say-on-pay vote is expected at the 2028 annual meeting of stockholders, and the next advisory vote on the frequency of executive compensation advisory votes will be at the 2031 annual meeting.

Management Comments

• Sandesh Seth, Chairman and CEO: "Your vote is very important, regardless of the number of shares of our voting securities that you own. Whether or not you expect to be present at the Annual Meeting, after receiving the Notice of Annual Meeting please vote as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting."
• Sandesh Seth, Chairman and CEO: "On behalf of the Board of Directors, I urge you to submit your vote as soon as possible, even if you currently plan to attend the meeting in person."
• Board of Directors: "The Board has determined that, for all employees, our compensation programs do not encourage excessive risk and instead encourage behaviors that support sustainable value creation."
• The Company and other Defendants: "intend to defend vigorously against such claims, however, there can be no assurances as to the outcome." (referring to legal proceedings)

Industry Context

This proxy statement primarily focuses on routine corporate governance matters, executive compensation, and auditor appointments for Actinium Pharmaceuticals, Inc., a company operating in the biotechnology/pharmaceutical sector. While it details internal corporate affairs, the mention of the Iomab-B Phase 3 Sierra Trial in legal proceedings indicates the company's involvement in clinical development within the industry.

Comparison to Industry Standards

• The document states that the CEO's base salary is adjusted to be competitively aligned to a range between the 25th and 75th percentile of relevant market data of chief executive officer positions of similarly situated publicly companies, indicating an effort to benchmark executive compensation.
• No specific comparisons to industry financial performance or operational metrics are provided within this filing.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Class Action Complaint**: Filed March 27, 2025, by Nitin Kohil against the Company and executives (Sandesh Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt) in the U.S. District Court for the Southern District of New York. The complaint alleges material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial. It seeks unspecified damages on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024. Lead plaintiffs were appointed on June 24, 2025, and intend to file an amended complaint by August 25, 2025.
• **Derivative Shareholder Complaints (Consolidated into Derivative Action)**: Two complaints, the Georges Complaint (May 5, 2025) and the Robinson Complaint (May 13, 2025), were filed against the Company and certain directors and officers. These complaints allege derivative liability for the same allegations made in the Securities Complaint. The complaints were consolidated on June 24, 2025. On July 29, 2025, the parties filed a stipulation to stay the Derivative Action pending resolution of any motion to dismiss the Securities Complaint. The Company and other Defendants intend to vigorously defend against these claims.

Related Party Transactions

• No transactions with related persons exceeding $120,000 or 1% of average total assets at year-end for the last two completed fiscal years were disclosed, other than compensation agreements and arrangements detailed in the Director Compensation and Executive Compensation sections.
• Executive officers have signed non-competition agreements, which include invention assignments and confidentiality clauses, ensuring protection of proprietary information.

Stakeholder Impact

• **Shareholders**: Will participate in key corporate governance decisions at the Annual Meeting, including director elections and advisory votes on executive compensation. They are directly impacted by the company's ongoing net losses and the significant decline in Total Shareholder Return. The outcome of the legal proceedings could also materially affect share value.
• **Employees/Directors**: Their compensation structure, including base salaries and performance bonuses, is detailed. The cancellation of stock options on March 31, 2025, impacts their equity holdings and aligns with long-term company interests.
• **Customers/Patients**: While not directly addressed, the legal proceedings concerning alleged misrepresentations about the Iomab-B Phase 3 Sierra Trial could indirectly affect public trust and future product perception.
• **Creditors**: The company's persistent net losses could be a concern for creditors regarding financial stability and ability to meet future obligations.

Next Steps

• Stockholders are to vote on director elections, auditor ratification, executive compensation, and the frequency of future advisory votes on executive compensation at the Annual Meeting on November 26, 2025.
• Lead plaintiffs in the Securities Complaint intend to file an amended complaint on or before August 25, 2025.
• The Company and other Defendants intend to vigorously defend against the legal claims.
• The next say-on-pay vote is expected at the 2028 annual meeting of stockholders.
• The next advisory vote on the frequency of executive compensation advisory votes will be at the 2031 annual meeting.

Key Dates

Recommendation

The company faces significant challenges, including persistent net losses, a substantial decline in Total Shareholder Return over the past three years, and active class-action and derivative lawsuits alleging material misrepresentations. These factors create considerable uncertainty and risk for investors. While the proxy statement addresses routine governance, the underlying financial performance and legal risks suggest a challenging outlook, warranting a 'sell' recommendation for a seasoned investor or institution.

Keywords

Actinium Pharmaceuticals, Proxy Statement, Annual Meeting, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, SEC Filing, Biotechnology, Pharmaceuticals, Legal Proceedings, Shareholder Vote, Net Loss, TSR